NCCN Optimizing Patient Outcomes - When Prognosis Changes from Good to Poor: Treatment Options for Richter Transformation of Chronic Lymphocytic Leukemia

May 6, 2026

Management of Richter transformation (RT) with conventional chemotherapy is largely met with poor responses and short survival. It is important to understand the role of novel therapies such as targeted agents including BTKis and BCL-2 inhibitors, immune checkpoint inhibitors, and anti-CD19 CAR T-cell therapies. Nearly all the information on RT comes from retrospective analysis and case series with limited data in newly diagnosed CLL patients. An increased understanding of the new therapy options will inspire clinicians to promote clinical trial participation and pave the way for the development of more effective treatments. 

Target Audience

This program is designed to meet the educational needs of physicians, nurses, nurse practitioners, pharmacists, physician associates and other health care professionals who treat patients with cancer.  

Learning Objectives

Following this activity, participants should be able to:

  • Identify and describe the signs, symptoms and risk factors associated with RT, including CLL stage, patient characteristics, and treatment related factors.
  • Interpret the clinical trial data for current and emerging treatment options for RT of CLL to aggressive large B-cell lymphoma.
  • Recognize the importance of clinical trials in advancing the treatment of RT and understand the current landscape of trials in this area to promote clinical trial awareness and participation.

You may also be interested in

Emerging Treatment Options for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

The use of BTKis and BCL2 inhibitors have significantly improved survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic leukemia (CLL/SLL).
Additional information
Supporters: 

Supported by educational grants from:

  • Johnson & Johnson
  • Genentech, a member of the Roche Group

This activity is supported by an independent educational grant from Regeneron Pharmaceuticals, Inc.

Course summary
Available credit: 
  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Course opens: 
01/22/2026
Course expires: 
07/25/2026
Event starts: 
05/06/2026 - 3:00pm EDT
Event ends: 
05/06/2026 - 4:00pm EDT
Part of: 
NCCN Webinar Series - Optimizing Patient Outcomes: Collaborative Perspectives in Oncology
Add to calendar: 
Molly Graveno, PharmD, BCOP
Huntsman Cancer Institute at the University of Utah
 
NCCN Continuing Education Disclosure Policy
 
It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates and discloses to learners all relevant financial relationships.
 
In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 
 
Definitions  
 
Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 
 
Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.
 
Faculty Disclaimers  
 
All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery. Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.
 
Faculty Disclosures
 
The faculty listed below has no financial relationships with ineligible companies to disclose.
 
Molly Graveno, PharmD, BCOP
 
NCCN Staff Disclosures
 
None of the planners for this educational activity have relevant financial relationships to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

image

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 1.0 contact hour. This activity offers 1.0 pharmacotherapeutic contact hour for nurses.

Pharmacists
NCCN designates this application-based continuing education activity for 1.0 contact hour (0.10 CEUs) of continuing education credit. UAN: JA4008196-0000-26-032-L01-P

PAs
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit. PAs should only claim credit commensurate with the extent of their participation.

Available Credit

  • 1.00 AAPA Category 1 CME credit
  • 1.00 ACPE contact hours
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 ANCC contact hours
    • 1.00 ANCC Pharmacology Contact Hours
  • 1.00 Participation
Please login or register to take this course.

Click the Take Course button to register for this live webinar/take the pre-test.

This webinar will be presented live one time only on Wednesday, May 6, 2026, 3:00 - 4:00 PM [EDT (UTC -4)]. To adjust for other time zones, click here.

 

NCCN Non-Discrimination/Harassment Policy – Affiliated Persons and Volunteers
NCCN is committed to providing workplaces and events that are free from discrimination or harassment of any kind for all participants, and has a zero-tolerance policy for any such conduct. NCCN requires individuals participating on NCCN Guidelines Panels, standing and ad hoc committees, meetings and seminars, or other NCCN-affiliated activities and events to adhere to this policy.

To access this policy including reporting procedures, please visit NCCN.org/non-discrimination.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing